Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models

@article{Smith2004ComparisonO1,
  title={Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models},
  author={Victoria Smith and Edward A. Sausville and Richard F. Camalier and H H Fiebig and Angelika M. Burger},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2004},
  volume={56},
  pages={126-137}
}
The heat shock protein Hsp90 is a potential target for drug discovery of novel anticancer agents. By affecting this protein, several cell signaling pathways may be simultaneously modulated. The geldanamycin analog 17AAG has been shown to inhibit Hsp90 and associated proteins. Its clinical use, however, is hampered by poor solubility and thus, difficulties in formulation. Therefore, a water-soluble derivative was desirable and 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) is such… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 55 extracted citations

Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2013
View 4 Excerpts
Highly Influenced

Hsp90: A New Player in DNA Repair?

Biomolecules • 2015
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 35 references

BRAF and RAS mutations in human lung cancer and melanoma.

Cancer research • 2002
View 4 Excerpts
Highly Influenced

Mutations of the BRAF gene in human cancer

Nature • 2002
View 4 Excerpts
Highly Influenced

A phase I trial of 17allylamino-geldanamycin (17-AAG) in patients with advanced cancer

C Ehrlichman, D Toft, +6 authors P Ivy
J Clin Oncol ASCO Annual Meeting Proc 22(14S):202 • 2004
View 1 Excerpt

Activate, mutated B-raf protein kinase requires the Hsp90 chaperone for folding and stability and is degraded in response to Hsp90 inhibitors (abstract 100)

OM Grbovic, AD Basso, +3 authors N Rosen
Proc Am Assoc Cancer Res • 2004
View 1 Excerpt

Similar Papers

Loading similar papers…